Expression Pathology

Movers & Shakers

Premium

William Wallen, Jonathan Knowles, Jon Burrows, Jenny Heidbrink, Sheeno Thyparambil

The firms will combine their respective technologies to identify and measure cancer-related protein targets.

Mayo applied the technology for solubilizing and capturing the protein content in FFPE tissue to develop a mass spectrometry-based method for the diagnosis and classification of amyloidosis in routine biopsy samples in a clinical setting. It will offer its test through its reference lab.

Mayo Clinic has licensed rights to IP that will be used in its test for for diagnosing and classifying amyloidosis.

The firm also said that it and NextGen Sciences have developed a protein biomarker assay method that can provide rapid, reproducible, quantitative measurement of protein expression in formalin-fixed, paraffin-embedded tissue.

The firm will use the funds to develop protein biomarker-based personalized medicine assays.

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.